Only two in ten eligible patients receive CAR-T: closing the gap starts in manufacturing
Cell and Gene Therapy Insights 2026; 12(8)
10.18609/cgti.2026.117
Published: 8 October
Infographic
Only around 20% of eligible US patients currently receive CAR-T therapy.
Drawing on the Cell & Gene Therapy Insights CAR-T Special Interest Group, this infographic examines the manufacturing barriers behind that gap and compares three routes to wider access: autologous, allogeneic, and in vivo CAR-T.
Read the full infographic below
Only around 20% of eligible US patients currently receive CAR-T therapy.
Drawing on the Cell & Gene Therapy Insights CAR-T Special Interest Group, this infographic examines the manufacturing barriers behind that gap and compares three routes to wider access: autologous, allogeneic, and in vivo CAR-T.
Read the full infographic below